Evidence map›Paper›PMID 31470537›Full record

ArticleMarine drugs2019

Sublingual Delivery of Astaxanthin through a Novel Ascorbyl Palmitate-Based Nanoemulsion: Preliminary Data.

Andrea Fratter, Damiano Biagi, Arrigo F G Cicero

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andrea FratterResearch and Innovation Technology, Nutraceutical Department, Labomar Research, 31036 Istrana, Italy.
Damiano BiagiResearch and Innovation Technology, Nutraceutical Department, Labomar Research, 31036 Istrana, Italy.
Arrigo F G CiceroMedical and Surgical Sciences Department, University of Bologna, 40138 Bologna, Italy. arrigo.cicero@unibo.it.ORCID 0000-0002-4367-3884

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astaxanthin is a carotenoid extracted from several seaweeds with ascertained therapeutic activity. With specific reference, astaxanthin is widely used in clinical practice to improve ocular tissue health and skin protection from UV ray damages. Despite its well-documented pleiotropic actions and demonstrated clinical efficacy, its bioavailability in humans is low and limited because of its hydrophobicity and poor dissolution in enteric fluids. Furthermore, astaxanthin is very unstable molecule and very sensitive to light exposure and thermal stress. Taken together, these pharmacological and chemical-physical features strongly limit pharmaceutical and nutraceutical development of astaxanthin-based products and as a consequence its full clinical usage. This work describes the preliminary in vitro investigation of sublingual absorption of astaxanthin through a novel ascorbyl palmitate (ASP) based nanoemulsion.

Indexed as

Biological AvailabilityEmulsionsHumansHydrophobic and Hydrophilic InteractionsNanoparticlesPalmitatesPreliminary DataSeaweedSolubilityXanthophyllsastaxanthineEmulsionsPalmitatesXanthophyllsascorbyl palmitateastaxanthinFranz cellnanoemulsionsublingual delivery

Identifiers

PMID31470537
PMCPMC6780925

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.